Sterile Tubing Welder Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Sterile Tubing Welder Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The sterile tubing welder market is expected to register a CAGR of 4% during the forecast period.

The outbreak of COVID-19 positively impacted the market due to the increasing use of sterilized hospital supplies and instruments to avoid contamination with coronavirus. Additionally, blood testing helps diagnose infectious diseases, such as COVID-19. Testing remains a crucial step in controlling the COVID-19 pandemic. As the number of COVID-19 cases increased worldwide, governments were exploring the possibility of allowing private laboratories to ramp up blood testing. People with weak immune systems, infected by COVID-19 and hospitalized, were in need of blood/plasma transfusion.

Market growth is attributed to increasing R&D expenditure and the growing demand for sterile tubing welders across hospitals and research clinics. The rising adoption of single-use technologies and increasing demand for blood and blood products also fuel the growth of the market. According to a 2021 report published by the National Institute of Health (NIH), an estimated 15 million units were transfused in 2021 in United States. These were transfused for the treatment of hematologic disorders, such as anemia, leUnited Kingdomemia, and sickle cell diseases.

An increase in blood transfusions led to a high demand and adoption of blood products, thus promoting the growth of the market. Moreover, the contamination of blood results in wastage, improper storage, and lack of proper handling associated with blood processing. These factors also boost the demand for automated sterile tubing welder, further driving the market.

Additionally, R&D expenditure across the pharmaceutical industry is increasing worldwide. For instance, data from clinicaltrials.gov suggests that over 6,000 pharmaceutical products were being evaluated worldwide as of 2022. With this, the spending on pharmaceutical R&D increased drastically. As pharmaceutical expenditure is on the rise, sterile tubing welwelders are believed to increase in the coming years, which will contribute to significant market growth.

However, the presence of alternatives for sterile tubing welders is expected to hinder market growth over the forecast period.

The application of sterile tubing welders in biopharmaceuticals is expected to witness rapid growth over the forecast period. Advanced biomanufacturing processes require advanced tools to provide reliable connections between components. With the rising use of sterile tubing welders in biopharmaceutical manufacturing, the segment is believed to witness strong growth over the forecast period.

Several major players in the market provide sterile tubing welders for biopharmaceutical applications. For instance, Sartorius provides an automated tool called the Biowelder TC, which is used to sterilize connections between TPE (thermoplastic elastomer) tube components. This tried-and-true method connects TPE tubing that is dry or liquid-filled using special rotating tube holders. It guarantees complete containment of process fluids by reattaching discarded tube ends. Validation procedures ensure sterile Biowelder TC connections. Other companies that provide these tools include Aseptic Group, which has a sterile tube welder known as Model 3960. The Model 3960 is designed for biopharmaceutical manufacturing applications where aseptic tubing connections are required. It is a stand-alone automated tabletop device that requires a minimal user interface for ease of operation.

Vante 360, developed by Vante Biopharm, is another device popularly used for dependable disconnection and connection of TPE, PVC, and EVA tubing used in biopharmaceutical and single-use manufacturing operations. Hence, with the presence of big companies in the segment, the availability of devices, and their increasing applications, the biopharmaceutical segment is expected to witness strong growth over the forecast period.

North America is expected to hold a significant market share in the global Sterile Tubing Welder Market due to the increasing demand for a hygienic and sterile environment, the rising prevalence of chronic diseases, technological advancements, healthcare expenditure, and the presence of well-established healthcare infrastructure. According to the American National Red Cross, 2021 updated estimates, approximately 36,000 units of red blood cells are needed every day, and nearly 21 million blood components are transfused each year in United States.

The growing demand for effective diagnostic solutions to obtain proper treatment for chronic diseases is also expected to drive market growth in United States. For instance, in the Cancer Facts & Figures 2022 data published by the American Cancer Society, an estimated 1.9 million new cancer cases will be diagnosed with 609,360 cancer deaths in United States. In addition, the US population aged 65 years or older accounted for 54.1 million (16% of the total population) in 2019, estimated to reach 21.6% by 2040. Hence, the prevalence of chronic diseases and the increasing geriatric population in the country are anticipated to create more opportunities for new drug developments which are expected to contribute to the growth of the market during the forecast period.

In North America, other countries including Canada are having a strong presence of companies that operate in the sterile tubing welder business. For instance, Terumo BCT, Sartorius, and Cytiva are some of the key players that provide sterile tubing welders across the Canadian market. With the presence of key players and the well-established healthcare industry, the market studied is expected to witness strong growth in Canada over the forecast period.

The sterile tubing welder market is moderately competitive and consists of several major players. Some companies that currently dominate the market are Cytiva (GE Healthcare), Terumo BCT Inc., Genesis BPS, MGA Technologies, Sartorius AG, Entegris, Inc., Biomen Biosystems Company Limited, and Vante Biopharm/Sebra.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support